Monoclonal antibodies
Articles filed under Monoclonal antibodies.
Ustekinumab for plaque psoriasis approved by FDA
Ustekinumab is a monoclonal antibody that targets IL-12 and IL-23, it is approved for the treatment of plaque psoriasis. Read the latest recommendations on its use.
TNF blockers and lymphoma: FDA adds boxed warning
FDA: TNF blockers increase the risk of lymphoma and other malignancies in children and adolescents. Drugs included: etanercept –Enbrel-, infliximab –Remicade- and adalimumab –HUMIRA-
Video lecture: Biologic therapies for inflammatory and autoimmune diseases
Dr. Chan explains how biologic therapy (mainly through monoclonal antibodies) is changing the present and future of autoimmune and inflammatory diseases. He illustrates some examples of autoimmune diseases such as: multiple sclerosis, asthma, treatment of rheumatoid arthritis with etanercept, and others.
Rituximab (Rituxan, MabThera): first line treatment for chronic lymphocytic leukemia
The UK’s National Institute for Health and Clinical Excellence (NICE) issued yesterday a guidance on the use of rituximab as first line treatment for chronic lymphocytic leukemia.
Mechanism of action, indications and adverse effects of: etanercept, infliximab and adalimumab
Etanercept, infliximab and adalimumab are TNF alpha blockers. Learn about TNF alpha in inflammation. Mechanism of action, therapeutic uses and adverse effects profile of these drugs.
Overview on monoclonal antibody therapy: PPT, images and videos
This post intends to be a brief and readable overview on what monoclonal antibodies (mAbs) are and some examples of their clinical applications. The following slideshow is a clear and accurate introduction on the topic: (ignore the first slide error message and move to the second)